niraparib
Sign in to saveAlso known as compound 56 [PMID 19873981], MK 4827, MK-4827, Zejula
Niraparib, sold under the brand name Zejula, is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is taken by mouth. It is a PARP inhibitor.
Key facts
- Drug.legal_AU
- S4
- Drug.image
- Niraparib.svg
- Drug.image_class
- skin-invert-image
- Drug.caption
- Above: molecular structure of niraparib Below: 3D representation of a niraparib molecule
- Drug.image2
- Niraparib 3D.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Zejula
- Drug.MedlinePlus
- a617007
- Drug.DailyMedID
- Niraparib
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- XK02
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- / Schedule D
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Research
986 papers- Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2024
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.The New England journal of medicine · 2019
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.The New England journal of medicine · 2016
- Niraparib.2012
via PubMed
~6 min read
Encyclopedic overview
12 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- Studies
- History
- References
- External links
Niraparib, sold under the brand name Zejula, is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is taken by mouth. It is a PARP inhibitor.
The most common side effects include nausea (feeling sick), thrombocytopenia (low blood platelet counts), tiredness and weakness, anemia (low red blood cell counts), constipation, vomiting, abdominal (belly) pain, neutropenia (low levels of neutrophils, a type of white blood cell), insomnia (difficulty sleeping), headache, lack of appetite, diarrhea, dyspnea (difficulty breathing), hypertension (high blood pressure), back pain, dizziness, cough, joint pain, hot flushes and decrease in white blood cells.
Excerpted from Wikipedia’s “niraparib” article, available under the CC BY-SA 4.0 licence.